Revel has tapped the Agilent Instrument Subscriptions Program to gain access to a mass spectrometer, critical in the startup’s work to combat the damages of aging.

Soteria, a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, announces $42 Million Series A Financing.

Alessa Therapeutics announces the enrollment of the first patient in their clinical study in Australia. The Biolen-PC study will treat up to 20 patients in Australia and New Zealand.

AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound.

The investment was led by professional and angel investor groups consisting of current and former pharmaceutical executives and physicians.

BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, announced it has raised $19 million in an oversubscribed Series A funding round.

The partnership will provide Charles River clients with access to Cypre’s proprietary 3D tumor model platform, Falcon-X™, which will expand Charles River’s 3D in vitro testing services to further optimize immuno-oncological approaches for its clients.

XPose Therapeutics and Accelero Biostructures, two of the MBC BioLabs San Carlos resident companies, announced research agreements.

Symbiome, the first skincare brand to create a collection of BioIntact™ products to nourish the skin microbiome, has officially launched today.

Symbiome, the first skincare brand to create a collection of BioIntact™ products to nourish the skin microbiome, has officially launched today.

Siolta Therapeutics, a clinical-stage biotech company and MBC BioLabs San Carlos resident company, has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H.

Symbiome is slated to launch Oct. 7 with seven products that aim to shift the skin’s microbiome back to its “ancestral” state, according to Larry Weiss, founder and chief scientific officer.

XPose Therapeutics is leveraging 3D structures of molecular fragments bound to drug targets to develop specific therapeutics.

IonLAST™, a novel hand sanitizer, kills germs on contact and, unlike common hand sanitizers, provides protection against their transmission for more than four hours after applying to skin.